GRI Bio, Inc. (GRI) stock
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.35−0.05 (-3.54%)
Close on Nov 17, 2026Market cap $2.95MP/E –Yield –
GRI Bio r&d expenses
Research and development expenses are spending on new products and technology.
GRI Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.17M, down 24.9% year over year. For fiscal 2025 it was $6.82M, up 81.0% from the year before. The highest annual figure on record is $6.82M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.82M | +81.0% |
| FY2024 | Dec 31, 2024 | $3.77M | +16.6% |
| FY2023 | Dec 31, 2023 | $3.23M | +1235.5% |
| FY2022 | Dec 31, 2022 | $242.00K | -95.3% |
| FY2021 | Dec 31, 2021 | $5.19M | +39.9% |
| FY2020 | Dec 31, 2020 | $3.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $407.00K | -78.3% |
| Q1 FY2026 | Mar 31, 2026 | $361.00K | -78.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.63M | +79.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.77M | +57.2% |
| Q2 FY2025 | Jun 30, 2025 | $1.88M | +114.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.64M | +75.8% |
| Q4 FY2024 | Dec 31, 2024 | $907.00K | -13.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.13M | -5.4% |
| Q2 FY2024 | Jun 30, 2024 | $877.00K | -0.3% |
| Q1 FY2024 | Mar 31, 2024 | $933.00K | +704.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.05M | +1614.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.19M | +1787.3% |
| Q2 FY2023 | Jun 30, 2023 | $880.00K | +1391.5% |
| Q1 FY2023 | Mar 31, 2023 | $116.00K | -90.9% |
| Q4 FY2022 | Dec 31, 2022 | $61.00K | -96.9% |
| Q3 FY2022 | Sep 30, 2022 | $63.00K | -70.7% |
| Q2 FY2022 | Jun 30, 2022 | $59.00K | -95.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.27M | -28.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.00M | +56.1% |
| Q3 FY2021 | Sep 30, 2021 | $215.00K | -70.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.20M | +48.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.77M | +100.7% |
| Q4 FY2020 | Dec 31, 2020 | $1.28M | – |
| Q3 FY2020 | Sep 30, 2020 | $733.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $808.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $883.00K | – |
See a number that looks wrong?